Page last updated: 2024-12-06
emitefur
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Emitefur: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 65910 |
| CHEMBL ID | 2104592 |
| SCHEMBL ID | 27921 |
| MeSH ID | M0361104 |
Synonyms (31)
| Synonym |
|---|
| last-f |
| emitefur |
| bof-a2 |
| m-((3-(ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2h)-pyrimidinyl)carbonyl)benzoic acid, 2-ester with 2,6-dihydroxynicotinonitrile benzoate (ester) |
| benzoic acid, 3-((3-(ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2h)-pyrimidinyl)carbonyl)-, 6-(benzoyloxy)-3-cyano-2-pyridinyl ester |
| benzoic acid, 3-((3-(etoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2h)-pyrimidinyl)carbonyl)-, 6-(benzoyloxy)-3-cyano-2-pyridinyl ester |
| ccris 6984 |
| emitefur [inn] |
| 3-(3-(6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl)-1-ethoxymethyl-5-fluorouracil |
| 3-(3-(6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl)-1-ethoxymethyl-5- fluorouracil |
| 3-((3-(ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2h)-pyrimidinyl)carbonyl)benzoic acid, 6-(benzoyloxy)-3-cyano-2-pyridinyl ester |
| m-((3-(ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2h)-pyrimidinyl)carbonyl)benzoic acid, 2-ester with 2,6-dihydroxynicotinonitrile, benzoate |
| 110690-43-2 |
| emitefur (usan/inn) |
| D03987 |
| (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate |
| unii-9i50nf4aq2 |
| emitefur [usan:inn] |
| 9i50nf4aq2 , |
| CHEMBL2104592 |
| AKOS016014066 |
| FT-0631052 |
| SCHEMBL27921 |
| emitefur [jan] |
| emitefur [usan] |
| emitefur [mi] |
| DTXSID80149360 |
| lastf |
| 6-(benzoyloxy)-3-cyanopyridin-2-yl 3-(3-(ethoxymethyl)-5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-1-carbonyl)benzoate |
| 3-[3-(6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl]-1-ethoxymethyl-5-fluorouracil |
| Q27272578 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "To determine the toxicities, dose-limiting toxicities (DLT), maximum-tolerated dose, and pharmacokinetic profile of emitefur (BOF-A2) in patients with advanced solid tumors." | ( Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors. Corey, A; Eager, R; Hoff, PM; Nemunaitis, J; Pazdur, R; Sekar, K; Thompson, J; Tkaczuk, K; Twaddell, T, 2000) | 0.75 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "8-30 mg/kg of BOF-A2) was orally administered every day to 5 mice in each dosage group for 4 weeks." | ( The inhibitory action of BOF-A2, a 5-fluorouracil derivative, on squamous cell carcinoma. Osaki, T; Ueta, E; Yamamoto, T; Yoneda, K, 1999) | 0.3 |
| " This variability makes effective dosing of 5-FU and related drugs difficult." | ( Oral DPD-inhibitory fluoropyrimidine drugs. Diasio, RB, 2000) | 0.31 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (27)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (7.41) | 18.7374 |
| 1990's | 20 (74.07) | 18.2507 |
| 2000's | 5 (18.52) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 17.17
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.17) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (11.11%) | 5.53% |
| Reviews | 10 (37.04%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (51.85%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||